News

Filter

Current filters:

Diabetes

226 to 235 of 744 results

Indication changes for Glufast approved in Japan

13-09-2013

Japanese drugmakers Kissei Pharmaceutical (TYO: 4547) and Takeda Pharmaceutical (TYO: 4502) have received…

Asia-PacificDiabetesGlufastKissei PharmaceuticalPharmaceuticalRegulationTakeda Pharmaceuticals

Sanofi temporarily pulls lixisenatide NDA in USA

12-09-2013

French drug major Sanofi (Euronext: SAN) this morning (September 12) announced its decision to withdraw…

DiabeteslixisenatideLyxumiaNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Interim results for ChemoCentryx' CCX140 fail to inspire

12-09-2013

US drug developer ChemoCentryx (Nasdaq: CCXI) announced interim data from an ongoing Phase II study in…

BiotechnologyCCX140ChemoCentryxDiabetesNephrology and HepatologyResearch

Depomed expands geographic scope of metformin deal with Merck

10-09-2013

USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

ThromboGenics gains rights to DME drug

06-09-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Novo Nordisk falls on loss of two US contracts

04-09-2013

Danish insulin giant Novo Nordisk (NOV: N) saw its shares fall 2.8% to 936 Danish kroner yesterday (September…

Bristol-Myers SquibbDiabetesEli LillyMarkets & MarketingNorth AmericaNovo NordiskNovoLogPharmaceuticalVictoza

Merck & Co to co-promote diabetes agent ipragliflozin in Japan

02-09-2013

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

226 to 235 of 744 results

COMPANY SPOTLIGHT

Menarini

Back to top